CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).
Epistemonikos ID: 80ae33aa73ca59757df6b909eeeae861bbbad94b
First added on: May 21, 2024